1-20 of 29
Hope S. Rugo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B019: Clinical and molecular correlates of circulating tumor DNA (ctDNA) dynamics in breast tumors resistant to neoadjuvant therapy (NAT)

Mark Jesus M. Magbanua, Denise M. Wolf, Samuel Rivera-Hinojosa, Ziad Ahmed, Nayelis A. Manon, Rosalyn Sayaman, Antony Tin, Ekaterina Kalashnikova, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau, Wen Li, Claudine Isaacs, Rebecca A. Shatsky, Amy L. Delson, Charuta C. Palsuledesai, Angel Rodriguez, Minetta C. Liu, Paula R. Pohlmann, Laura J. Esserman, Hope S. Rugo, Angela DeMichele, Laura van 't Veer
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B019.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B019
Published: 13 November 2024
View article titled, Abstract B019: Clinical and molecular correlates of circulating tumor DNA (ctDNA) dynamics in breast tumors resistant to neoadjuvant therapy (NAT)
Journal Articles

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Mark Jesus M. Magbanua, Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Jane Perlmutter, Paula Pohlmann, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela M. DeMichele, Hope S. Rugo, Laura J. van 't Veer
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2444–2451.
https://doi.org/10.1158/1078-0432.CCR-23-2928
Published: 03 June 2024
View article titled, Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Open the PDF for Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, Lajos Pusztai, David Euhus, Rita Nanda, Anthony D. Elias, Amy S. Clark, Constantine Godellas, Judy C. Boughey, Claudine Isaacs, Debu Tripathy, Janice Lu, Rachel L. Yung, Rosa I. Gallagher, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Gregor Krings, Yunn Yi Chen, David A. Potter, Erica Stringer-Reasor, Sarah Blair, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Adam L. Asare, Jeffrey B. Matthews, Angela M. DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van't Veer, Douglas Yee, Donald A. Berry, Laura J. Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 729–740.
https://doi.org/10.1158/1078-0432.CCR-22-2256
Published: 16 February 2024
View article titled, Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Open the PDF for Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery in another window
Includes: Supplementary data
Journal Articles

Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?

Laura A. Huppert, Hope S. Rugo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 4993–4995.
https://doi.org/10.1158/1078-0432.CCR-23-1909
Published: 15 December 2023
View article titled, Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?
Open the PDF for Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer? in another window
Journal Articles

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma

Hope S. Rugo, Kira Raskina, Alexa B. Schrock, Russell W. Madison, Ryon P. Graf, Ethan S. Sokol, Smruthy Sivakumar, Jessica K. Lee, Virginia Fisher, Geoffrey R. Oxnard, Hanna Tukachinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1056–1067.
https://doi.org/10.1158/1078-0432.CCR-22-2115
Published: 14 March 2023
View article titled, Biology and Targetability of the Extended Spectrum of <em>PIK3CA</em> Mutations Detected in Breast Carcinoma
Open the PDF for Biology and Targetability of the Extended Spectrum of <em>PIK3CA</em> Mutations Detected in Breast Carcinoma in another window
Includes: Supplementary data
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

Joanne L. Blum, A. Douglas Laird, Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri H. Roché, Kyung-Hun Lee, Annabel Goodwin, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Julia F. Hopkins, Lee A. Albacker, Lida A. Mina
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1383–1390.
https://doi.org/10.1158/1078-0432.CCR-21-2080
Published: 01 April 2022
View article titled, Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer
Open the PDF for Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

Siang-Boon Koh, Kenneth Ross, Steven J. Isakoff, Nsan Melkonjan, Lei He, Karina J. Matissek, Andrew Schultz, Erica L. Mayer, Tiffany A. Traina, Lisa A. Carey, Hope S. Rugo, Minetta C. Liu, Vered Stearns, Adam Langenbucher, Srinivas Vinod Saladi, Sridhar Ramaswamy, Michael S. Lawrence, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4883–4897.
https://doi.org/10.1158/1078-0432.CCR-21-0714
Published: 01 September 2021
View article titled, RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Open the PDF for RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes

David A. Potter, Alexandra Thomas, Hope S. Rugo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4486–4490.
https://doi.org/10.1158/1078-0432.CCR-21-1133
Published: 15 August 2021
View article titled, A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes
Open the PDF for A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes in another window
Journal Articles

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Aditya Bardia, Sara A. Hurvitz, Angela DeMichele, Amy S. Clark, Amelia Zelnak, Denise A. Yardley, Meghan Karuturi, Tara Sanft, Sibel Blau, Lowell Hart, Cynthia Ma, Hope S. Rugo, Das Purkayastha, Stacy Moulder
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (15): 4177–4185.
https://doi.org/10.1158/1078-0432.CCR-20-2114
Published: 01 August 2021
View article titled, Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Open the PDF for Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) in another window
Includes: Supplementary data
Journal Articles

Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer

Hope S. Rugo, Laura Huppert
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3275–3277.
https://doi.org/10.1158/1078-0432.CCR-21-0353
Published: 15 June 2021
View article titled, Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer
Open the PDF for Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer in another window
Journal Articles

Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting

Navid Hafez, Hope S. Rugo, Margaret A. Tempero, Elizabeth Fox, Gregory H. Reaman, Herbert Kim Lyerly, Desiree Walker, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4743–4747.
https://doi.org/10.1158/1078-0432.CCR-19-4035
Published: 15 September 2020
View article titled, Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting
Open the PDF for Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting in another window
Journal Articles

Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

Mark Jesus M. Magbanua, Oleksandr Savenkov, Erik J. Asmus, Karla V. Ballman, Janet H. Scott, John W. Park, Maura Dickler, Ann Partridge, Lisa A. Carey, Eric P. Winer, Hope S. Rugo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4911–4920.
https://doi.org/10.1158/1078-0432.CCR-20-1329
Published: 15 September 2020
View article titled, Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab
Open the PDF for Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab in another window
Includes: Supplementary data
Journal Articles

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

Melody Cobleigh, Denise A. Yardley, Adam M. Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (5): 1105–1113.
https://doi.org/10.1158/1078-0432.CCR-19-2350
Published: 02 March 2020
View article titled, Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
Open the PDF for Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer

Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martin, Hope S. Rugo, Véronique Diéras, Seock-Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongrui R. Lu, Eric Gauthier, Cynthia Huang Bartlett, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-19-0751
Published: 03 January 2020
View article titled, Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Open the PDF for Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Andrew M. Wardley, Colombe Chappey, Alison L. Hannah, Mark E. Robson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2717–2724.
https://doi.org/10.1158/1078-0432.CCR-18-1891
Published: 01 May 2019
View article titled, A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <em>BRCA1/2</em> Mutations (ABRAZO)
Open the PDF for A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <em>BRCA1/2</em> Mutations (ABRAZO) in another window
Includes: Supplementary data
Journal Articles

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (8): 2433–2441.
https://doi.org/10.1158/1078-0432.CCR-18-2366
Published: 15 April 2019
View article titled, Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Open the PDF for Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs in another window
Includes: Supplementary data
Journal Articles

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Bert H. O’Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, Yukihide Momozawa, Michiaki Kubo, Donna Niedzwiecki, Howard S. Hochster, Heinz-Josef Lenz, James N. Atkins, Hope S. Rugo, Susan Halabi, William Kevin Kelly, Howard L. McLeod, Federico Innocenti, Mark J. Ratain, Alan P. Venook, Kouros Owzar, Deanna L. Kroetz
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4734–4744.
https://doi.org/10.1158/1078-0432.CCR-17-1523
Published: 01 October 2018
View article titled, Identification of a Genomic Region between <em>SLC29A1</em> and <em>HSP90AB1</em> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Open the PDF for Identification of a Genomic Region between <em>SLC29A1</em> and <em>HSP90AB1</em> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) in another window
Includes: Supplementary data
Journal Articles

Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

Hope S. Rugo, Javier Cortes, Ahmad Awada, Joyce O'Shaughnessy, Chris Twelves, Seock-Ah Im, Alison Hannah, Lin Lu, Sherwin Sy, Katie Caygill, Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3348–3357.
https://doi.org/10.1158/1078-0432.CCR-17-3059
Published: 15 July 2018
View article titled, Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Open the PDF for Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol in another window
Includes: Supplementary data
Journal Articles

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Hope S. Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A. Ott, Sarina A. Piha-Paul, Philippe L. Bedard, Jasgit Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andrea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2804–2811.
https://doi.org/10.1158/1078-0432.CCR-17-3452
Published: 14 June 2018
View article titled, Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Open the PDF for Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in another window
Includes: Supplementary data